Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Do we effectively lower blood pressure?

L M Ruilope1

  • 1Hypertension Unit, Hospital 12 de Octubre, Madrid, Spain.

Journal of Cardiovascular Pharmacology
|June 15, 2000
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Finerenone protects against progression of kidney and cardiovascular damage in a model of type 1 diabetes through modulation of proinflammatory and osteogenic factors.

Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie·2023
Same author

Oral health, hypertension and cardiovascular diseases.

Hipertension y riesgo vascular·2023
Same author

Counteracting aldosterone in cardiorenal disease in type 2 diabetes through finerenone administration.

Hipertension y riesgo vascular·2022
Same author

[2022 Practice guidelines for the management of arterial hypertension of the Spanish Society of Hypertension].

Hipertension y riesgo vascular·2022
Same author

2021 Spanish Society of Hypertension position statement about telemedicine.

Hipertension y riesgo vascular·2021
Same author

[Awareness, treatment and control of blood pressure according to place of recruitment and sex in the May Measure Month 2018 survey in Spain].

Hipertension y riesgo vascular·2020
Same journal

Prophylactic ACE inhibition in anthracycline-induced cardiotoxicity: signal, context, and clinical uncertainty.

Journal of cardiovascular pharmacology·2026
Same journal

Imipramine Can Block Human Cardiac H1-Histamine Receptors.

Journal of cardiovascular pharmacology·2026
Same journal

Ivabradine in the Treatment of POTS Before and After COVID-19 Pandemic: A Systematic Review and Meta-Analysis.

Journal of cardiovascular pharmacology·2026
Same journal

Mineralocorticoid receptor antagonists in managing hypertension: a link with diurnal patterns of blood pressure.

Journal of cardiovascular pharmacology·2026
Same journal

The Cardiac Sarcomere: From development of heritable cardiomyopathies to gene and precision therapies.

Journal of cardiovascular pharmacology·2026
Same journal

Efficacy and Safety of Lorundrostat for Uncontrolled and Treatment-resistant Hypertension: A Systematic Review and Meta-analysis of Randomized Controlled Trials.

Journal of cardiovascular pharmacology·2026
See all related articles

Effective blood pressure control is crucial for reducing cardiovascular risk in hypertension. Aggressive treatment strategies and optimized combination therapies are essential, particularly for high-risk individuals, to improve patient outcomes.

Area of Science:

  • Cardiology
  • Pharmacology
  • Hypertension Management

Background:

  • Elevated cardiovascular risk in hypertensive populations necessitates improved blood pressure control.
  • Current blood pressure management strategies are often insufficient for optimal risk normalization.
  • High-risk hypertensive patients require more aggressive therapeutic approaches.

Purpose of the Study:

  • To emphasize the need for enhanced blood pressure control strategies in hypertension.
  • To advocate for the wider adoption of combined antihypertensive therapies.
  • To explore the potential benefits of carefully selected combination components for blood pressure-independent effects.

Main Methods:

  • Review of current hypertension management guidelines and clinical trial data.

Related Experiment Videos

  • Analysis of treatment strategies, including pharmacological therapies and combination approaches.
  • Consideration of findings from large-scale studies such as the Hypertension Optimal Treatment (HOT) study.

    • Main Results:

    • Current blood pressure control remains suboptimal in many hypertensive patients.
    • Combined antihypertensive therapy, when appropriately selected, shows promise for improved efficacy.
    • Blood pressure-independent effects of certain drug combinations may offer additional cardiovascular protection.

    Conclusions:

    • A more aggressive approach to blood pressure management is warranted, especially in high-risk individuals.
    • Optimized selection and utilization of combined antihypertensive therapies are critical for effective cardiovascular risk reduction.
    • Further research into blood pressure-independent mechanisms of combination therapies could enhance protective strategies.